Global Amyotrophic Lateral Sclerosis Treatment Market, By Type (Sporadic ALS and Familial ALS), By Drug Type (Riluzole, Edaravone, and Nuedexta), By Treatment (Medication, Respiratory Therapy, Speech Therapy, Physical Therapy, Chemotherapy, Stem Cell Therapy, and Other Treatments), By End Users (Hospitals, Speciality Centres, Research and Academic Institutes, Diagnostic Centres, and Other End-Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 49399
- Number of Pages: 295
- Format:
-
keyboard_arrow_up
-
-
- Sanofi Company Profile
- Mitsubishi Tanabe Pharma Corporation
- BrainStorm Cell Limited
- Mylan N.V.
- Ionis Pharmaceuticals
- Biogen
- Covis Pharma
- Apotex Inc.
- Ascend Laboratories LLC
- ITF Pharma
- Genervon Biopharmaceuticals, LLC
- Bausch Health Companies Inc.
- ORPHAZYME A/S
- Orion Pharma Ltd.
- KRINGLE PHARMA, INC.
- Amylyx Pharmaceuticals Inc
- Sun Pharmaceutical Industries Ltd.
- Advanz Pharmaceutical
- Otsuka Pharmaceutical Co., Ltd.
- Other Key Players
- settingsSettings
Our Clients
- 49399
- Oct 2023
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
